{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:28:53Z","timestamp":1791559733863,"version":"4.3.4"},"reference-count":29,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,5,8]]},"published-print":{"date-parts":[[2025,11]]},"DOI":"10.2967\/jnumed.125.269601","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T14:00:34Z","timestamp":1749132034000},"page":"1714-1721","source":"Crossref","is-referenced-by-count":12,"title":["<sup>225<\/sup>\n                    Ac \u03b1-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2\u2013Expressing Breast Cancer"],"prefix":"10.2967","volume":"66","author":[{"given":"Sara S.","family":"Rinne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Burnes Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Veach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"McDevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Fen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward K.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana C.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai Kong V.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Cheal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025110708450920000_66.11.1714.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00579-0"},{"key":"2025110708450920000_66.11.1714.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00849-9"},{"key":"2025110708450920000_66.11.1714.3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41392-019-0069-2","article-title":"Targeted therapeutic options and future perspectives for HER2-positive breast cancer","volume":"4","author":"Wang","year":"2019","journal-title":"Signal Transduct Target Ther."},{"key":"2025110708450920000_66.11.1714.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3925"},{"key":"2025110708450920000_66.11.1714.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1064126"},{"key":"2025110708450920000_66.11.1714.6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41181-023-00208-0","article-title":"[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in\u00a0vitro and tumour and normal tissue uptake in\u00a0vivo in NRG mice with HER2-positive human breast cancer xenografts","volume":"8","author":"Kondo","year":"2023","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2025110708450920000_66.11.1714.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262186"},{"key":"2025110708450920000_66.11.1714.8","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.7150\/thno.26585","article-title":"Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: curative treatment of HER2-positive breast carcinoma","volume":"8","author":"Cheal","year":"2018","journal-title":"Theranostics."},{"key":"2025110708450920000_66.11.1714.9","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.7150\/thno.48810","article-title":"Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors: safety at curative doses","volume":"10","author":"Cheal","year":"2020","journal-title":"Theranostics."},{"key":"2025110708450920000_66.11.1714.10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/acs.bioconjchem.0c00595","article-title":"Engineered cells as a test platform for radiohaptens in pretargeted imaging and radioimmunotherapy applications","volume":"32","author":"Dacek","year":"2021","journal-title":"Bioconjug Chem."},{"key":"2025110708450920000_66.11.1714.11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1021\/acs.bioconjchem.9b00736","article-title":"An N-acetylgalactosamino dendron-clearing agent for high-therapeutic-index DOTA-hapten pretargeted radioimmunotherapy","volume":"31","author":"Cheal","year":"2020","journal-title":"Bioconjug Chem."},{"key":"2025110708450920000_66.11.1714.12","doi-asserted-by":"crossref","first-page":"e1267891","DOI":"10.1080\/2162402X.2016.1267891","article-title":"Overcoming resistance to HER2-targeted therapy with a novel HER2\/CD3 bispecific antibody","volume":"6","author":"Lopez-Albaitero","year":"2017","journal-title":"Oncoimmunology."},{"key":"2025110708450920000_66.11.1714.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.187021"},{"key":"2025110708450920000_66.11.1714.14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1021\/acs.molpharmaceut.4c01071","article-title":"Preclinical Comparison of [111In]In- and [225Ac]Ac-DOTA-trastuzumab IgG, F(ab\u2032)2 and Fab\u2032 for theranostic SPECT\/CT imaging and alpha-particle radioimmunotherapy of HER2-positive human breast cancer","volume":"22","author":"Kondo","year":"2025","journal-title":"Mol Pharm."},{"key":"2025110708450920000_66.11.1714.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2025110708450920000_66.11.1714.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193250"},{"key":"2025110708450920000_66.11.1714.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-014-0047-1"},{"key":"2025110708450920000_66.11.1714.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265095"},{"key":"2025110708450920000_66.11.1714.19","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29865"},{"key":"2025110708450920000_66.11.1714.20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0207"},{"key":"2025110708450920000_66.11.1714.21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00259-020-05094-1","article-title":"HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging","volume":"48","author":"Altunay","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025110708450920000_66.11.1714.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.075101"},{"key":"2025110708450920000_66.11.1714.23","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62(suppl 3)","author":"Wahl","year":"2021","journal-title":"J Nucl Med."},{"key":"2025110708450920000_66.11.1714.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05474-1"},{"key":"2025110708450920000_66.11.1714.25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/atm-23-1842","article-title":"Design of 225Ac-PSMA for targeted alpha therapy in prostate cancer","volume":"12","author":"Kairemo","year":"2024","journal-title":"Ann Transl Med."},{"key":"2025110708450920000_66.11.1714.26","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00259-007-0713-x","article-title":"Differences in radiosensitivity between three HER2 overexpressing cell lines","volume":"35","author":"Steffen","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025110708450920000_66.11.1714.27","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.3390\/cancers14112784","article-title":"Factors influencing the therapeutic efficacy of the PSMA targeting radioligand 212Pb-NG001","volume":"14","author":"Stenberg","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2025110708450920000_66.11.1714.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2150"},{"key":"2025110708450920000_66.11.1714.29","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004110945"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T16:46:22Z","timestamp":1762533982000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,3]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.2967\/jnumed.125.269601"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269601","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}